Rosetta Genomics Is Considering Options To Sell Pragmin

Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The Company is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The Company's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The Company focuses on developing a diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification.